Adaptive Biotechnologies Co. (NASDAQ:ADPT) Short Interest Update

Adaptive Biotechnologies Co. (NASDAQ:ADPT) was the target of a significant growth in short interest in the month of November. As of November 30th, there was short interest totalling 9,580,000 shares, a growth of 16.8% from the November 15th total of 8,200,000 shares. Based on an average daily trading volume, of 1,190,000 shares, the short-interest ratio is presently 8.1 days.

Adaptive Biotechnologies Trading Up 2.3 %

Shares of NASDAQ ADPT opened at $6.30 on Friday. The company has a 50 day simple moving average of $5.37 and a two-hundred day simple moving average of $4.58. The stock has a market cap of $929.75 million, a price-to-earnings ratio of -4.70 and a beta of 1.49. Adaptive Biotechnologies has a 12 month low of $2.28 and a 12 month high of $7.07.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on ADPT shares. Piper Sandler upped their target price on Adaptive Biotechnologies from $6.00 to $7.00 and gave the company an “overweight” rating in a research report on Monday, November 11th. BTIG Research boosted their price target on Adaptive Biotechnologies from $7.00 to $8.00 and gave the company a “buy” rating in a research note on Wednesday, October 2nd.

Institutional Investors Weigh In On Adaptive Biotechnologies

Several hedge funds have recently bought and sold shares of the stock. JTC Employer Solutions Trustee Ltd acquired a new position in shares of Adaptive Biotechnologies in the 3rd quarter valued at $26,000. Ashton Thomas Securities LLC purchased a new position in Adaptive Biotechnologies in the third quarter valued at $34,000. Rothschild Investment LLC acquired a new position in shares of Adaptive Biotechnologies in the second quarter worth about $36,000. MQS Management LLC acquired a new position in Adaptive Biotechnologies in the 2nd quarter worth about $36,000. Finally, Nisa Investment Advisors LLC boosted its position in Adaptive Biotechnologies by 769.6% during the second quarter. Nisa Investment Advisors LLC now owns 13,392 shares of the company’s stock worth $48,000 after purchasing an additional 11,852 shares in the last quarter. Hedge funds and other institutional investors own 99.17% of the company’s stock.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.